Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim’s Spiriva shows benefits in large-scale trial

Boehringer Ingelheim’s Spiriva shows benefits in large-scale trial

9th September 2013

Boehringer Ingelheim has reported positive data from Tiospir, a large-scale clinical study of its chronic obstructive pulmonary disease (COPD) drug Spiriva.

The Tiospir trial was one of the largest international COPD trials ever conducted – involving more than 17,000 patients – and confirmed the comparable safety and efficacy profile of the two available Spiriva formulations, Spiriva Respimat and Spiriva HandiHaler.

It was revealed that both versions of the therapy provided strong performances in terms of safety and efficacy, suggesting its suitability among a broad population of COPD patients, including those with a history of cardiac disease.

Trial investigator Professor Antonio Anzueto of the University of Texas Health Science Center at San Antonio, said: "The critical message from this large-scale Tiospir trial is that physicians can be confident that they can prescribe this proven maintenance therapy across the severity spectrum of COPD patients."

The data was presented by Boehringer Ingelheim at the annual congress of the European Respiratory Society, which is taking place in Barcelona this week.ADNFCR-8000103-ID-801634970-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.